Posted in | News | Nanobusiness

Pre-Clinical Study Agreement for Evaluation of NanoViricides' Drug Candidate for Herpes Keratitis of the Eye

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that it has signed a pre-clinical study agreement for the evaluation of NanoViricides' drug candidate for herpes keratitis of the eye. The study will be conducted by Thevac, LLC, a spin-off of the Louisiana State University (LSU), Baton Rouge, LA. It will be performed in collaboration with the Division of Biotechnology and Molecular Medicine at the LSU School of Veterinary Medicine, which administers the LSU-Tulane Center for Experimental Infectious Disease Research (Director, K. G. Kousoulas, PhD).

Herpes keratitis (herpes virus infection of the cornea) is a serious, potentially blinding disease of the eye. It is the leading infectious cause of blindness in developed countries and the most common infectious corneal disease in the United States. It can often necessitate corneal transplantation. Herpes virus infections and adenoviral infections of the cornea together constitute most of the viral disease of the external eye. At present, there is no satisfactory treatment that works for both adenoviral and herpesvirus keratitis/conjunctivitis. The potential domestic market for a drug effective against all or most viral infections of the external eye is variously estimated to be from $500M to billions of dollars.

“We are very pleased to have a recognized expert like Dr. Kousoulas associated with this study,” said Eugene Seymour, MD, MPH, Chief Executive Officer of NanoViricides, Inc., adding, “This will provide us with independent results for the nanoviricide™ drug candidates against viral diseases of the external eye. Separate studies are expected to begin shortly in collaboration with a pharmaceutical company.”

“The NanoViricides technology appears to be very promising for treating a variety of viral diseases including influenza,” says Dr. Kousoulas.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoViricides, Inc. (2019, February 14). Pre-Clinical Study Agreement for Evaluation of NanoViricides' Drug Candidate for Herpes Keratitis of the Eye. AZoNano. Retrieved on April 18, 2024 from https://www.azonano.com/news.aspx?newsID=11403.

  • MLA

    NanoViricides, Inc. "Pre-Clinical Study Agreement for Evaluation of NanoViricides' Drug Candidate for Herpes Keratitis of the Eye". AZoNano. 18 April 2024. <https://www.azonano.com/news.aspx?newsID=11403>.

  • Chicago

    NanoViricides, Inc. "Pre-Clinical Study Agreement for Evaluation of NanoViricides' Drug Candidate for Herpes Keratitis of the Eye". AZoNano. https://www.azonano.com/news.aspx?newsID=11403. (accessed April 18, 2024).

  • Harvard

    NanoViricides, Inc. 2019. Pre-Clinical Study Agreement for Evaluation of NanoViricides' Drug Candidate for Herpes Keratitis of the Eye. AZoNano, viewed 18 April 2024, https://www.azonano.com/news.aspx?newsID=11403.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.